Top

Published in:

01-05-2016

Classification and diagnosis of pulmonary hypertension

Authors: Hector R. Cajigas, Rana Awdish

Published in: Heart Failure Reviews | Issue 3/2016

Abstract

Pulmonary hypertension has been classified into five major subgroups in order to better understand and apply knowledge from the areas of molecular biology, pathophysiology and clinical science. Accurate classification of the patient not only optimizes diagnostic approach but also confers the best benefit, as therapeutic approaches are applied accurately. Current diagnostic strategies begin with a detailed history and physical, which are directed to elucidate symptoms that may increase the degree of suspicion. Subsequent application of a logical approach to progress through the diagnostic algorithm , with understanding of the complexity of this process, allows for best possible outcomes. Proper diagnosis and classification will eventually increase the potential for appropriate research and progress toward of a possible cure for this fatal disease.

Simonneau G et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–D41CrossRefPubMed

Le Pavec J et al (2010) Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 181(12):1285–1293CrossRefPubMedPubMedCentral

Coghlan JG et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRefPubMedPubMedCentral

Ruiz-Irastorza G et al (2013) Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 12(3):410–415CrossRefPubMed

Gunnarsson R et al (2013) Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology (Oxford) 52(7):1208–1213CrossRef

Chung L et al (2014) Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 146(6):1494–1504CrossRefPubMedPubMedCentral

Sitbon O et al (2008) Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177(1):108–113CrossRefPubMed

Krowka MJ et al (2006) Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 44(6):1502–1510CrossRefPubMed

Krowka MJ et al (2012) Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 141(4):906–915CrossRefPubMed

10.

Marelli AJ et al (2014) Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 130(9):749–756CrossRefPubMed

11.

Ferreira RC et al (2009) Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis. Ann Trop Med Parasitol 103(2):129–143CrossRefPubMed

12.

Lapa M et al (2009) Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 119(11):1518–1523CrossRefPubMed

13.

Goncalves EC, Fonseca AP, Pittella JE (1995) Frequency of schistosomiasis mansoni, of its clinicopathological forms and of the ectopic locations of the parasite in autopsies in Belo Horizonte, Brazil. J Trop Med Hyg 98(5):289–295PubMed

14.

Fonseca GH et al (2012) Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 39(1):112–118CrossRefPubMed

15.

Parent F et al (2011) A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 365(1):44–53CrossRefPubMed

16.

Agarwal R et al (2012) Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. J Heart Lung Transpl 31(5):467–477CrossRef

17.

Leung CC et al (2010) Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 106(2):284–286CrossRefPubMed

18.

Gerges C et al (2013) Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest 143(3):758–766CrossRefPubMed

19.

Gerges M et al (2015) Pulmonary hypertension in heart failure: epidemiology, right ventricular function and survival. Am J Respir Crit Care Med. doi:10.1164/rccm.201503-0529OC

20.

Vachiéry JL et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(25 SUPPL.):D100–D108CrossRefPubMed

21.

Hoeper MM et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42–D50CrossRefPubMed

22.

McLaughlin VV et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Associati. Circulation 119(16):2250–2294CrossRefPubMed

23.

Galie N et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493–2537CrossRefPubMed

24.

Kaul S et al (1984) Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 107(3):526–531CrossRefPubMed

25.

Ghio S et al (2002) Usefulness and limits of transthoracic echocardiography in the evaluation of patients with primary and chronic thromboembolic pulmonary hypertension. J Am Soc Echocardiogr 15(11):1374–1380CrossRefPubMed

26.

Rich JD et al (2011) Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 139(5):988–993CrossRefPubMed

27.

Janda S et al (2011) Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 97(8):612–622CrossRefPubMed

28.

Fine NM et al (2013) Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging 6(5):711–721CrossRefPubMed

29.

Unlu S et al (2015) Apical traction: a novel visual echocardiographic parameter to predict survival in patients with pulmonary hypertension. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jev131

30.

Grewal J et al (2010) Three-dimensional echocardiographic assessment of right ventricular volume and function in adult patients with congenital heart disease: comparison with magnetic resonance imaging. J Am Soc Echocardiogr 23(2):127–133CrossRefPubMed

31.

Pennell DJ et al (2004) Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 25(21):1940–1965CrossRefPubMed

32.

Shors SM et al (2004) Accurate quantification of right ventricular mass at MR imaging by using cine true fast imaging with steady-state precession: study in dogs. Radiology 230(2):383–388CrossRefPubMed

33.

Grothues F et al (2004) Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 147(2):218–223CrossRefPubMed

34.

Vonk Noordegraaf A (2015) Noninvasive imaging in the assessment of the cardiopulmonary vascular unit. Circulation 131(10):899–913CrossRefPubMed

35.

Chaouat A et al (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172(2):189–194CrossRefPubMed

36.

Hamada K et al (2007) Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131(3):650–656CrossRefPubMed

37.

Minai OA et al (2012) Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med 106(11):1613–1621CrossRefPubMed

38.

Nathan SD et al (2008) Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 76(3):288–294CrossRefPubMed

39.

Rich S et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107(2):216–223CrossRefPubMed

40.

Burke CM et al (1987) Pulmonary function in advanced pulmonary hypertension. Thorax 42(2):131–135CrossRefPubMedPubMedCentral

41.

Meyer FJ et al (2002) Peripheral airway obstruction in primary pulmonary hypertension. Thorax 57(6):473–476CrossRefPubMedPubMedCentral

42.

Miyamoto S et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 Pt 1):487–492CrossRefPubMed

43.

Humbert M et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122(2):156–163CrossRefPubMed

44.

Benza RL et al (2010) Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 122(2):164–172CrossRefPubMed

45.

Sitbon O et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40(4):780–788CrossRefPubMed

46.

Savarese G et al (2012) Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 60(13):1192–1201CrossRefPubMed

47.

Gabler NB et al (2012) Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126(3):349–356CrossRefPubMedPubMedCentral

48.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1): 111–117CrossRef

49.

Korkmaz A et al (2012) Long-term outcomes in acute pulmonary thromboembolism: the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors. Clin Appl Thromb Hemost 18(3):281–288CrossRefPubMed

50.

Bonderman D et al (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93(3):512–516PubMed

51.

Condliffe R et al (2009) Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J 33(2):332–338CrossRefPubMed

52.

Tunariu N et al (2007) Ventilation–perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48(5):680–684CrossRefPubMed

53.

Lisbona R et al (1985) Perfusion lung scanning: differentiation of primary from thromboembolic pulmonary hypertension. AJR Am J Roentgenol 144(1):27–30CrossRefPubMed

54.

Auger WR et al (2012) Evaluation of patients with chronic thromboembolic pulmonary hypertension for pulmonary endarterectomy. Pulm Circ 2(2):155–162CrossRefPubMedPubMedCentral

55.

Hoeper MM et al (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48(12):2546–2552CrossRefPubMed

56.

Kovacs G et al (2013) Zero reference level for right heart catheterisation. Eur Respir J 42(6):1586–1594CrossRefPubMed

57.

LeVarge BL, Pomerantsev E, Channick RN (2014) Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J 44(2):425–434CrossRefPubMedPubMedCentral

58.

Halpern SD, Taichman DB (2009) Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 136(1):37–43CrossRefPubMed

59.

Hoeper MM et al (1999) Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 160(2):535–541CrossRefPubMed

60.

Montani D et al (2010) Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 31(15):1898–1907CrossRefPubMed

Title: Classification and diagnosis of pulmonary hypertension
Authors: Hector R. Cajigas
Rana Awdish
Publication date: 01-05-2016
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 3/2016
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-015-9512-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Classification and diagnosis of pulmonary hypertension

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure

Pulmonary hypertension associated with lung diseases and hypoxemia

Medical therapies for pulmonary arterial hypertension

The right ventricle and pulmonary hypertension

Molecular pathogenesis and current pathology of pulmonary hypertension

Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page